Loading...

Home
Stock
VNRX

VNRX Overview

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

Loading chart...

High

2.628

Open

2.290

VWAP

2.42

Vol

220.22K

Mkt Cap

19.58M

Low

2.280

Amount

532.84K

EV/EBITDA(TTM)

--

Total Shares

8.33M

EV

26.33M

EV/OCF(TTM)

--

P/S(TTM)

3.91

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

Show More

Events Timeline

(ET)

2026-05-14

16:20:00

Cameron Reynolds: Nu.Q Vet Cat Test to Unlock $5 Million Milestone

2026-05-06 (ET)

2026-05-06

08:20:00

VolitionRx Submits Study on Feline Lymphoma Detection

2026-04-29 (ET)

2026-04-29

08:20:00

VolitionRx Successfully Detects Nucleosomes in Sepsis Patients

2026-04-23 (ET)

2026-04-23

08:20:00

VolitionRx Receives Acceptance of Compliance Plan from NYSE American

2026-03-06 (ET)

2026-03-06

08:20:00

VolitionRx Completes Validation of Nu.Q Vet Cancer Test

2026-02-09 (ET)

2026-02-09

17:30:00

VolitionRx Receives NYSE Warning, Must Submit Compliance Plan

2026-02-09

17:20:00

VolitionRx Files to Sell 17.97M Shares of Common Stock

News

Yahoo Finance

05-15Yahoo Finance

VolitionRX Reports Significant Q1 2026 Revenue Growth

Significant Revenue Growth: VolitionRX Ltd (VNRX) reported approximately $1 million in revenue for Q1 2026, a 300% increase from $0.2 million in Q1 2025, primarily driven by deferred revenue recognition from a new QVET agreement with HESCA, indicating strong growth potential in the veterinary business.
Rising Operating Expenses: Operating expenses increased to $6.3 million in Q1 2026 from $5.8 million in Q1 2025, partly due to severance costs and higher R&D expenses, which may exert short-term pressure on the company's profitability.
Cash Flow Situation: The net cash used in operating activities rose to $5.3 million in Q1 2026, compared to $4.3 million in the same period last year, reflecting changes in supplier payment timing that could impact the company's liquidity management.
Expansion of Collaboration Network: The company has entered into a non-exclusive agreement with Medical and Biological Labs Co. in Japan to accelerate disease research and drug development, demonstrating VNRX's proactive efforts to expand its partner network and market influence.

seekingalpha

05-15seekingalpha

VolitionRx Limited Reports Q1 2026 Earnings with Key Milestones

Significant Revenue Growth: VolitionRx reported approximately $1 million in revenue for Q1 2026, a 400% increase from $0.2 million in the same period of 2025, primarily driven by a rise in deferred revenue recognition from the Nu.Q Vet agreement with Heska, indicating strong potential in the veterinary diagnostics market.
Rising Operating Expenses: Operating expenses for the quarter reached $6.3 million, including severance costs related to cost reduction actions and increased R&D expenses, while cash and cash equivalents stood at $3.1 million, highlighting challenges in cost control and R&D advancement.
Accelerated Clinical Progress: CEO Cameron Reynolds emphasized strong progress in Nu.Q Vet automation, having completed validation of the chemiluminescent immunoassay, which is expected to significantly enhance lab efficiency and potentially unlock a $5 million contractual milestone payment, further driving revenue growth.
Cautious Future Outlook: Management stated that they will not provide revenue guidance for 2026, emphasizing the lumpiness of revenues, and indicated plans to engage with regulatory authorities in the coming months to advance reimbursement for Nu.Q Lung Cancer, reflecting uncertainty on the commercialization path.

seekingalpha

05-15seekingalpha

VolitionRX Q1 Earnings Beat Expectations with Significant Revenue Growth

Earnings Report: VolitionRX reported a Q1 GAAP EPS of -$0.97, missing expectations by $0.26, indicating ongoing challenges in achieving profitability.
Revenue Surge: The company generated $0.99M in revenue, reflecting a substantial year-over-year increase of 296.0%, exceeding market expectations by $0.46M, which suggests a significant uptick in product demand that could lay the groundwork for future profitability.
Financial Position: As of March 31, 2026, VolitionRX had cash and cash equivalents of $3.1M and an accumulated deficit of $259.6M, highlighting pressures on the company's financial management and ongoing operations.
Future Outlook: VolitionRX anticipates routine use of its Nu.Q cancer test in France by Q4 2026 while targeting a 25%-30% reduction in cash operating expenses for 2026, aiming to improve its financial health.

Newsfilter

05-11Newsfilter

VolitionRx to Host Q1 2026 Earnings Call

Earnings Call Announcement: VolitionRx will host a conference call on May 15, 2026, at 8:30 a.m. U.S. Eastern Time to discuss its financial and operational results for Q1 2026, which is expected to provide significant insights into the company's future direction.
Executive Participation: The call will be hosted by Group Chief Marketing & Communications Officer Louise Batchelor, with participation from President and CEO Cameron Reynolds and CFO Terig Hughes, highlighting the company's commitment to financial transparency.
Key Updates: The conference will cover important events from Q1 2026, subsequent developments, and upcoming milestones, aiming to communicate the company's progress in the field of early disease detection to investors.
Replay Information: A telephone replay of the call will be available until May 29, 2026, providing a convenient way for investors who could not attend live to access critical information.

Newsfilter

04-29Newsfilter

VolitionRx Achieves Major Milestone in Blood Testing Technology

Technical Breakthrough: VolitionRx successfully detects nucleosomes in capillary blood from critically ill sepsis patients, marking a significant milestone for its lateral flow prototype test, which is expected to enhance early diagnostic capabilities and improve patient outcomes.
Market Potential: The test can be utilized in emergency rooms, doctor's offices, or home self-testing, significantly expanding the market, particularly in low-income countries where there is a pressing need for rapid and convenient testing solutions.
Strategic Partnerships: Volition plans to establish strategic collaborations with NGOs and companies operating in low-income countries to accelerate commercialization efforts and further penetrate the global market.
Industry Impact: With approximately 166 million cases of sepsis worldwide and sepsis-related deaths accounting for 31.5% of total global deaths in 2021, the introduction of this technology is poised to transform traditional hospital infrastructure testing models and enhance healthcare efficiency.

seekingalpha

04-23seekingalpha

VolitionRx Receives NYSE Compliance Plan Approval

Compliance Plan Approval: VolitionRx (VNRX) has received approval from NYSE American for its compliance plan to maintain its listing, marking a significant step in addressing its stockholder equity deficiencies.
Historical Violation Context: The company was flagged on February 6, 2026, for failing to meet minimum stockholder equity requirements, primarily due to recurring financial losses, indicating vulnerabilities in its financial health.
Compliance Timeline: VolitionRx submitted its compliance plan before the March 8, 2026 deadline, with the exchange granting until August 6, 2027, to regain compliance, reflecting the exchange's confidence in the company's future prospects.
Financial Outlook: The company anticipates routine use of its Nu.Q cancer test in France by Q4 2026 while targeting a 25%-30% reduction in cash operating expenses for 2026, demonstrating its strategic intent in cost control and market expansion.

Wall Street analysts forecast VNRX stock price to rise

3 Analyst Rating

Wall Street analysts forecast VNRX stock price to rise

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

1.50

Averages

2.25

High

3.00

Current: 0.000

Low

1.50

Averages

2.25

High

3.00

D. Boral Capital

Buy

to

Hold

downgrade

$NULL

AI Analysis

2026-04-20

Reason

D. Boral Capital

Price Target

$NULL

AI Analysis

2026-04-20

downgrade

Buy

to

Hold

Reason

D. Boral Capital downgraded VolitionRx to Hold from Buy without a price target citing the company's 1-for-20 reverse stock split, effective April 28. Reverse splits are typically a negative for shareholders because they often signal financial stress, listing pressure, and limited strategic alternatives rather than underlying business strength, the analyst tells investors in a research note.

H.C. Wainwright

H.C. Wainwright

Buy

downgrade

$1

2026-04-02

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

$1

2026-04-02

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on VolitionRx to $1 from $1.50 and keeps a Buy rating on the shares after the company reported Q4 results. The firm, which believes that the company could secure additional human licensing deals in 2026 to help drive topline revenue growth, cites an increased share count for its lowered target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VNRX

Unlock Now

Valuation Metrics

The current forward P/E ratio for VolitionRX Ltd (VNRX.A) is 10.53, compared to its 5-year average forward P/E of -2.75. For a more detailed relative valuation and DCF analysis to assess VolitionRX Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.75

Current PE

10.53

Overvalued PE

1.62

Undervalued PE

-7.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.34

Current EV/EBITDA

-0.05

Overvalued EV/EBITDA

0.34

Undervalued EV/EBITDA

-3.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

59.03

Current PS

0.32

Overvalued PS

150.00

Undervalued PS

-31.95

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

all penny stocks out there

Intellectia · 1059 candidates

Region: USPrice: $0.00 - $5.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

iSpecimen Inc

3.23M

Maison Solutions Inc

4.26M

Virax Biolabs Group Ltd

1.10M

Cheetah Net Supply Chain Service Inc (Pre-Reincorporation)

60.78M

VolitionRX Ltd

25.37M

Lixiang Education Holding Co Ltd

3.45M

Intellectia · 4 candidates

Market Cap: 20.00M - 500.00MRegion: USPrice: $0.01 - $0.25List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

NUBURU Inc

29.84M

VolitionRX Ltd

26.28M

KALA BIO Inc

185.00M

Outlook Therapeutics Inc

26.05M

sort list ny market cap

Intellectia · 32 candidates

Price: $0.00 - $0.25Volume: >= 500,000Market Cap Category: micro, nano

Ticker

Name

Market Cap$

KALA BIO Inc

185.00M

Nakamoto Inc

150.98M

Hyperscale Data Inc

62.91M

Srx Health Solutions Inc

45.86M

Atlasclear Holdings Inc

35.12M

NUBURU Inc

29.84M

top penny stocks under $0.25

Intellectia · 32 candidates

Price: $0.00 - $0.25Volume: >= 500,000Market Cap Category: micro, nano

Ticker

Name

Market Cap$

iSpecimen Inc

3.80M

Wellgistics Health Inc

12.58M

zSpace, Inc.

2.85M

Virax Biolabs Group Ltd

1000.00K

Hyperscale Data Inc

62.91M

CXApp Inc

10.40M

What are the top penny stocks under $0.25

Intellectia · 26 candidates

Price: $0.00 - $0.25Volume: >= 500,000Market Cap Category: micro, nanoList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Quince Therapeutics Inc

10.20M

Hyperscale Data Inc

54.64M

Inno Holdings Inc

8.75M

Virax Biolabs Group Ltd

1.11M

Hub Cyber Security Ltd

431.94K

NUBURU Inc

29.16M

penny stocks under $1.00

Intellectia · 330 candidates

Price: $0.00 - $1.00Market Cap Category: micro, nanoList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Jet.AI Inc

9.67M

zSpace, Inc.

3.46M

Quince Therapeutics Inc

4.87M

Cenntro Inc (The Corporation)

10.22M

Hub Cyber Security Ltd

161.60K

Scworx Corp

1.98M

penny stocks positive most active today

Intellectia · 75 candidates

Price: $0.10 - $5.00Volume: >= 1,000,000Price Change Pct: >= $0.10

Ticker

Name

Market Cap$

ICZOOM Group Inc

10.57M

Peloton Interactive Inc

1.88B

Denison Mines Corp

3.08B

Kosmos Energy Ltd

1.73B

Baytex Energy Corp

3.20B

Globavend Holdings Ltd

3.20M

Help me find stocks that are under 2.00

Intellectia · 531 candidates

Region: USPrice: <= $2.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Applied Therapeutics Inc

14.24M

China SXT Pharmaceuticals Inc

11.42M

Jin Medical International Ltd

25.25M

Cenntro Inc (The Corporation)

13.35M

NUBURU Inc

76.36M

urban-gro Inc

3.10M

biotech industry stock under 5 dollars

Intellectia · 282 candidates

Industry: Biotechnology & Medical ResearchPrice: <= $5.00

Ticker

Name

Market Cap$

Applied Therapeutics Inc

14.63M

Theriva Biologics Inc

6.85M

IO Biotech Inc

14.94M

Adial Pharmaceuticals Inc

6.04M

GRI Bio Inc

2.26M

Propanc Biopharma Inc

3.62M

stovks to buy on wed from 20 to 40 cents

Intellectia · 81 candidates

Price: $0.20 - $0.40

Ticker

Name

Market Cap$

Sangamo Therapeutics Inc

127.97M

Incannex Healthcare Inc

123.43M

Hyperscale Data Inc

96.48M

Aurelion Inc

95.26M

Robo.ai Inc

89.22M

CleanCore Solutions Inc

79.36M

Whales Holding VNRX

Trading Trends

Insider

Hedge Fund

Congress Trading

People Also Watch

Frequently Asked Questions

What is VolitionRX Ltd (VNRX) stock price today?

The current price of VNRX is 2.35 USD — it has increased 3.07

What is VolitionRX Ltd (VNRX)'s business?

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

What is the price predicton of VNRX Stock?

Wall Street analysts forecast VNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNRX is2.25 USD with a low forecast of 1.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is VolitionRX Ltd (VNRX)'s revenue for the last quarter?

VolitionRX Ltd revenue for the last quarter amounts to 985.08K USD, increased 299.81

What is VolitionRX Ltd (VNRX)'s earnings per share (EPS) for the last quarter?

VolitionRX Ltd. EPS for the last quarter amounts to -19.37 USD, increased 1629.46

How many employees does VolitionRX Ltd (VNRX). have?

VolitionRX Ltd (VNRX) has 75 emplpoyees as of May 20 2026.

What is VolitionRX Ltd (VNRX) market cap?

Today VNRX has the market capitalization of 19.58M USD.